Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2011

Conditions
Precancerous Condition
Interventions
BIOLOGICAL

Rituximab

Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).

Trial Locations (3)

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Biogen

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER